Review





Similar Products

hpac  (ATCC)
96
ATCC hpac
A . Flow cytometry analysis of ALPP/ALPPL2 expression. PDAC cells were treated with Vehicle, KRASi for 2 days (MRTX1133, 100 nM), or KRASi for 7 days (MRTX1133, 20 nM). Representative histograms of three independent experiments are shown. B . Quantification of ALPP/ALPPL2 surface expression from flow cytometry in A . Mean fluorescence intensity was normalized to vehicle control; error bars denote mean ± s.d., n = 3 biological replicates. Statistical significance was determined by one-way ANOVA. C . ALPP/ALPPL2 protein levels in PDAC cells treated for 6 hours or 2 days with KRASi (MRTX1133, 100 nM for <t>AsPC-1,</t> Panc 02.03, SUIT-2, <t>HPAC,</t> and SW1990; 1 µM for PANC-1) or for 7 days with KRASi (MRTX1133, 20 nM for AsPC-1, Panc 02.03, SUIT-2, HPAC, and SW1990; 1 µM for PANC-1) determined by western blotting. D . Immunofluorescence analysis of PDAC cells stained for ALPP treated with DMSO or 100 nM MRTX1133 for 2 days. Scale bar = 50 µm. E. Internalization of the anti-ALPP/ALPPL2 or IgG antibody (10 nM), quantified by total integrated density by Incucyte live-cell imaging. AsPC-1 and HPAC cells were treated with and without KRASi (MRTX1133; 100 nM for AsPC-1, 10 nM for HPAC). F. Published RNAseq data from six KRAS G12D PDAC PDX models treated with 30 mg/kg BID MRTX1133 for 3 days . Boxes show median and interquartile range with individual tumors overlaid. Unpaired t-tests on log 10 (CPM+1) values were performed within each model, Šídák-Bonferroni corrected for multiple comparisons (ns, not significant; *P<0.05; **P<0.01). G. ALPP/ALPPL2, phospho-STAT3 (Y705), STAT3, phospho-ERK (T202/Y204), and ERK protein levels in PDAC cells treated with a non-targeting control siRNA (siCTRL) or two different siRNAs targeting STAT3 (siSTAT3) for 2 days before treatment with KRASi (100 nM MRTX1133 for AsPC-1 and SW1990, 1 µM MRTX1133 for PANC-1) for 2 days, determined by western blotting. Representative of three biological replicates. H . Relative ALPP/ALPPL2 mRNA levels measured by qPCR in the same samples as shown in G , error bars denote mean ± s.d., n = 3 independent repeats. Statistical significance was determined by one-way ANOVA. Representative of three biological replicates. I . Relative ALPP/ALPPL2 mRNA levels in PDAC cells treated with DMSO, KRASi (MRTX1133, 100 nM for AsPC-1; 1 µM for PANC-1), JAKi (Cucurbitacin I, 250 nM), or a combination of KRASi and JAKi for 2 days as measured by qPCR, error bars denote mean ± s.d., n = 3 independent repeats; representative of 3 biological replicates. Statistical significance was determined by one-way ANOVA
Hpac, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hpac/HPAC/bio_rxiv__64898__2026__10__01__756025-218-4-11
Average 96 stars, based on 1 article reviews
hpac - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
ATCC hpac cells
A . Flow cytometry analysis of ALPP/ALPPL2 expression. PDAC cells were treated with Vehicle, KRASi for 2 days (MRTX1133, 100 nM), or KRASi for 7 days (MRTX1133, 20 nM). Representative histograms of three independent experiments are shown. B . Quantification of ALPP/ALPPL2 surface expression from flow cytometry in A . Mean fluorescence intensity was normalized to vehicle control; error bars denote mean ± s.d., n = 3 biological replicates. Statistical significance was determined by one-way ANOVA. C . ALPP/ALPPL2 protein levels in PDAC cells treated for 6 hours or 2 days with KRASi (MRTX1133, 100 nM for <t>AsPC-1,</t> Panc 02.03, SUIT-2, <t>HPAC,</t> and SW1990; 1 µM for PANC-1) or for 7 days with KRASi (MRTX1133, 20 nM for AsPC-1, Panc 02.03, SUIT-2, HPAC, and SW1990; 1 µM for PANC-1) determined by western blotting. D . Immunofluorescence analysis of PDAC cells stained for ALPP treated with DMSO or 100 nM MRTX1133 for 2 days. Scale bar = 50 µm. E. Internalization of the anti-ALPP/ALPPL2 or IgG antibody (10 nM), quantified by total integrated density by Incucyte live-cell imaging. AsPC-1 and HPAC cells were treated with and without KRASi (MRTX1133; 100 nM for AsPC-1, 10 nM for HPAC). F. Published RNAseq data from six KRAS G12D PDAC PDX models treated with 30 mg/kg BID MRTX1133 for 3 days . Boxes show median and interquartile range with individual tumors overlaid. Unpaired t-tests on log 10 (CPM+1) values were performed within each model, Šídák-Bonferroni corrected for multiple comparisons (ns, not significant; *P<0.05; **P<0.01). G. ALPP/ALPPL2, phospho-STAT3 (Y705), STAT3, phospho-ERK (T202/Y204), and ERK protein levels in PDAC cells treated with a non-targeting control siRNA (siCTRL) or two different siRNAs targeting STAT3 (siSTAT3) for 2 days before treatment with KRASi (100 nM MRTX1133 for AsPC-1 and SW1990, 1 µM MRTX1133 for PANC-1) for 2 days, determined by western blotting. Representative of three biological replicates. H . Relative ALPP/ALPPL2 mRNA levels measured by qPCR in the same samples as shown in G , error bars denote mean ± s.d., n = 3 independent repeats. Statistical significance was determined by one-way ANOVA. Representative of three biological replicates. I . Relative ALPP/ALPPL2 mRNA levels in PDAC cells treated with DMSO, KRASi (MRTX1133, 100 nM for AsPC-1; 1 µM for PANC-1), JAKi (Cucurbitacin I, 250 nM), or a combination of KRASi and JAKi for 2 days as measured by qPCR, error bars denote mean ± s.d., n = 3 independent repeats; representative of 3 biological replicates. Statistical significance was determined by one-way ANOVA
Hpac Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hpac/HPAC/10__3390_slash_ph19101538-164-20-26
Average 96 stars, based on 1 article reviews
hpac cells - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

crl  (ATCC)
96
ATCC crl
A . Flow cytometry analysis of ALPP/ALPPL2 expression. PDAC cells were treated with Vehicle, KRASi for 2 days (MRTX1133, 100 nM), or KRASi for 7 days (MRTX1133, 20 nM). Representative histograms of three independent experiments are shown. B . Quantification of ALPP/ALPPL2 surface expression from flow cytometry in A . Mean fluorescence intensity was normalized to vehicle control; error bars denote mean ± s.d., n = 3 biological replicates. Statistical significance was determined by one-way ANOVA. C . ALPP/ALPPL2 protein levels in PDAC cells treated for 6 hours or 2 days with KRASi (MRTX1133, 100 nM for <t>AsPC-1,</t> Panc 02.03, SUIT-2, <t>HPAC,</t> and SW1990; 1 µM for PANC-1) or for 7 days with KRASi (MRTX1133, 20 nM for AsPC-1, Panc 02.03, SUIT-2, HPAC, and SW1990; 1 µM for PANC-1) determined by western blotting. D . Immunofluorescence analysis of PDAC cells stained for ALPP treated with DMSO or 100 nM MRTX1133 for 2 days. Scale bar = 50 µm. E. Internalization of the anti-ALPP/ALPPL2 or IgG antibody (10 nM), quantified by total integrated density by Incucyte live-cell imaging. AsPC-1 and HPAC cells were treated with and without KRASi (MRTX1133; 100 nM for AsPC-1, 10 nM for HPAC). F. Published RNAseq data from six KRAS G12D PDAC PDX models treated with 30 mg/kg BID MRTX1133 for 3 days . Boxes show median and interquartile range with individual tumors overlaid. Unpaired t-tests on log 10 (CPM+1) values were performed within each model, Šídák-Bonferroni corrected for multiple comparisons (ns, not significant; *P<0.05; **P<0.01). G. ALPP/ALPPL2, phospho-STAT3 (Y705), STAT3, phospho-ERK (T202/Y204), and ERK protein levels in PDAC cells treated with a non-targeting control siRNA (siCTRL) or two different siRNAs targeting STAT3 (siSTAT3) for 2 days before treatment with KRASi (100 nM MRTX1133 for AsPC-1 and SW1990, 1 µM MRTX1133 for PANC-1) for 2 days, determined by western blotting. Representative of three biological replicates. H . Relative ALPP/ALPPL2 mRNA levels measured by qPCR in the same samples as shown in G , error bars denote mean ± s.d., n = 3 independent repeats. Statistical significance was determined by one-way ANOVA. Representative of three biological replicates. I . Relative ALPP/ALPPL2 mRNA levels in PDAC cells treated with DMSO, KRASi (MRTX1133, 100 nM for AsPC-1; 1 µM for PANC-1), JAKi (Cucurbitacin I, 250 nM), or a combination of KRASi and JAKi for 2 days as measured by qPCR, error bars denote mean ± s.d., n = 3 independent repeats; representative of 3 biological replicates. Statistical significance was determined by one-way ANOVA
Crl, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hpac/HPAC/pm42221815-182-98-102
Average 96 stars, based on 1 article reviews
crl - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
ATCC cell lines
A . Flow cytometry analysis of ALPP/ALPPL2 expression. PDAC cells were treated with Vehicle, KRASi for 2 days (MRTX1133, 100 nM), or KRASi for 7 days (MRTX1133, 20 nM). Representative histograms of three independent experiments are shown. B . Quantification of ALPP/ALPPL2 surface expression from flow cytometry in A . Mean fluorescence intensity was normalized to vehicle control; error bars denote mean ± s.d., n = 3 biological replicates. Statistical significance was determined by one-way ANOVA. C . ALPP/ALPPL2 protein levels in PDAC cells treated for 6 hours or 2 days with KRASi (MRTX1133, 100 nM for <t>AsPC-1,</t> Panc 02.03, SUIT-2, <t>HPAC,</t> and SW1990; 1 µM for PANC-1) or for 7 days with KRASi (MRTX1133, 20 nM for AsPC-1, Panc 02.03, SUIT-2, HPAC, and SW1990; 1 µM for PANC-1) determined by western blotting. D . Immunofluorescence analysis of PDAC cells stained for ALPP treated with DMSO or 100 nM MRTX1133 for 2 days. Scale bar = 50 µm. E. Internalization of the anti-ALPP/ALPPL2 or IgG antibody (10 nM), quantified by total integrated density by Incucyte live-cell imaging. AsPC-1 and HPAC cells were treated with and without KRASi (MRTX1133; 100 nM for AsPC-1, 10 nM for HPAC). F. Published RNAseq data from six KRAS G12D PDAC PDX models treated with 30 mg/kg BID MRTX1133 for 3 days . Boxes show median and interquartile range with individual tumors overlaid. Unpaired t-tests on log 10 (CPM+1) values were performed within each model, Šídák-Bonferroni corrected for multiple comparisons (ns, not significant; *P<0.05; **P<0.01). G. ALPP/ALPPL2, phospho-STAT3 (Y705), STAT3, phospho-ERK (T202/Y204), and ERK protein levels in PDAC cells treated with a non-targeting control siRNA (siCTRL) or two different siRNAs targeting STAT3 (siSTAT3) for 2 days before treatment with KRASi (100 nM MRTX1133 for AsPC-1 and SW1990, 1 µM MRTX1133 for PANC-1) for 2 days, determined by western blotting. Representative of three biological replicates. H . Relative ALPP/ALPPL2 mRNA levels measured by qPCR in the same samples as shown in G , error bars denote mean ± s.d., n = 3 independent repeats. Statistical significance was determined by one-way ANOVA. Representative of three biological replicates. I . Relative ALPP/ALPPL2 mRNA levels in PDAC cells treated with DMSO, KRASi (MRTX1133, 100 nM for AsPC-1; 1 µM for PANC-1), JAKi (Cucurbitacin I, 250 nM), or a combination of KRASi and JAKi for 2 days as measured by qPCR, error bars denote mean ± s.d., n = 3 independent repeats; representative of 3 biological replicates. Statistical significance was determined by one-way ANOVA
Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hpac/HPAC/us12624033-1070-0-4
Average 96 stars, based on 1 article reviews
cell lines - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
ATCC crl 2119tm

Crl 2119tm, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hpac/HPAC/pmc13130678-72-4-2
Average 96 stars, based on 1 article reviews
crl 2119tm - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
ATCC hpac atcc

Hpac Atcc, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hpac/HPAC/pm41916312-755-81-82
Average 96 stars, based on 1 article reviews
hpac atcc - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

Image Search Results


A . Flow cytometry analysis of ALPP/ALPPL2 expression. PDAC cells were treated with Vehicle, KRASi for 2 days (MRTX1133, 100 nM), or KRASi for 7 days (MRTX1133, 20 nM). Representative histograms of three independent experiments are shown. B . Quantification of ALPP/ALPPL2 surface expression from flow cytometry in A . Mean fluorescence intensity was normalized to vehicle control; error bars denote mean ± s.d., n = 3 biological replicates. Statistical significance was determined by one-way ANOVA. C . ALPP/ALPPL2 protein levels in PDAC cells treated for 6 hours or 2 days with KRASi (MRTX1133, 100 nM for AsPC-1, Panc 02.03, SUIT-2, HPAC, and SW1990; 1 µM for PANC-1) or for 7 days with KRASi (MRTX1133, 20 nM for AsPC-1, Panc 02.03, SUIT-2, HPAC, and SW1990; 1 µM for PANC-1) determined by western blotting. D . Immunofluorescence analysis of PDAC cells stained for ALPP treated with DMSO or 100 nM MRTX1133 for 2 days. Scale bar = 50 µm. E. Internalization of the anti-ALPP/ALPPL2 or IgG antibody (10 nM), quantified by total integrated density by Incucyte live-cell imaging. AsPC-1 and HPAC cells were treated with and without KRASi (MRTX1133; 100 nM for AsPC-1, 10 nM for HPAC). F. Published RNAseq data from six KRAS G12D PDAC PDX models treated with 30 mg/kg BID MRTX1133 for 3 days . Boxes show median and interquartile range with individual tumors overlaid. Unpaired t-tests on log 10 (CPM+1) values were performed within each model, Šídák-Bonferroni corrected for multiple comparisons (ns, not significant; *P<0.05; **P<0.01). G. ALPP/ALPPL2, phospho-STAT3 (Y705), STAT3, phospho-ERK (T202/Y204), and ERK protein levels in PDAC cells treated with a non-targeting control siRNA (siCTRL) or two different siRNAs targeting STAT3 (siSTAT3) for 2 days before treatment with KRASi (100 nM MRTX1133 for AsPC-1 and SW1990, 1 µM MRTX1133 for PANC-1) for 2 days, determined by western blotting. Representative of three biological replicates. H . Relative ALPP/ALPPL2 mRNA levels measured by qPCR in the same samples as shown in G , error bars denote mean ± s.d., n = 3 independent repeats. Statistical significance was determined by one-way ANOVA. Representative of three biological replicates. I . Relative ALPP/ALPPL2 mRNA levels in PDAC cells treated with DMSO, KRASi (MRTX1133, 100 nM for AsPC-1; 1 µM for PANC-1), JAKi (Cucurbitacin I, 250 nM), or a combination of KRASi and JAKi for 2 days as measured by qPCR, error bars denote mean ± s.d., n = 3 independent repeats; representative of 3 biological replicates. Statistical significance was determined by one-way ANOVA

Journal: bioRxiv

Article Title: KRAS inhibition drives adaptive surfaceome remodeling and reveals ALPP/ALPPL2 as a targetable vulnerability in pancreatic cancer

doi: 10.64898/2026.10.01.756025

Figure Lengend Snippet: A . Flow cytometry analysis of ALPP/ALPPL2 expression. PDAC cells were treated with Vehicle, KRASi for 2 days (MRTX1133, 100 nM), or KRASi for 7 days (MRTX1133, 20 nM). Representative histograms of three independent experiments are shown. B . Quantification of ALPP/ALPPL2 surface expression from flow cytometry in A . Mean fluorescence intensity was normalized to vehicle control; error bars denote mean ± s.d., n = 3 biological replicates. Statistical significance was determined by one-way ANOVA. C . ALPP/ALPPL2 protein levels in PDAC cells treated for 6 hours or 2 days with KRASi (MRTX1133, 100 nM for AsPC-1, Panc 02.03, SUIT-2, HPAC, and SW1990; 1 µM for PANC-1) or for 7 days with KRASi (MRTX1133, 20 nM for AsPC-1, Panc 02.03, SUIT-2, HPAC, and SW1990; 1 µM for PANC-1) determined by western blotting. D . Immunofluorescence analysis of PDAC cells stained for ALPP treated with DMSO or 100 nM MRTX1133 for 2 days. Scale bar = 50 µm. E. Internalization of the anti-ALPP/ALPPL2 or IgG antibody (10 nM), quantified by total integrated density by Incucyte live-cell imaging. AsPC-1 and HPAC cells were treated with and without KRASi (MRTX1133; 100 nM for AsPC-1, 10 nM for HPAC). F. Published RNAseq data from six KRAS G12D PDAC PDX models treated with 30 mg/kg BID MRTX1133 for 3 days . Boxes show median and interquartile range with individual tumors overlaid. Unpaired t-tests on log 10 (CPM+1) values were performed within each model, Šídák-Bonferroni corrected for multiple comparisons (ns, not significant; *P<0.05; **P<0.01). G. ALPP/ALPPL2, phospho-STAT3 (Y705), STAT3, phospho-ERK (T202/Y204), and ERK protein levels in PDAC cells treated with a non-targeting control siRNA (siCTRL) or two different siRNAs targeting STAT3 (siSTAT3) for 2 days before treatment with KRASi (100 nM MRTX1133 for AsPC-1 and SW1990, 1 µM MRTX1133 for PANC-1) for 2 days, determined by western blotting. Representative of three biological replicates. H . Relative ALPP/ALPPL2 mRNA levels measured by qPCR in the same samples as shown in G , error bars denote mean ± s.d., n = 3 independent repeats. Statistical significance was determined by one-way ANOVA. Representative of three biological replicates. I . Relative ALPP/ALPPL2 mRNA levels in PDAC cells treated with DMSO, KRASi (MRTX1133, 100 nM for AsPC-1; 1 µM for PANC-1), JAKi (Cucurbitacin I, 250 nM), or a combination of KRASi and JAKi for 2 days as measured by qPCR, error bars denote mean ± s.d., n = 3 independent repeats; representative of 3 biological replicates. Statistical significance was determined by one-way ANOVA

Article Snippet: AsPC-1, Panc1, Panc0203, Panc0403, HPAC, and SW1990 cells were obtained from ATCC, and SUIT2, KP-4, KP-1N were obtained from the JCRB Cell Bank.

Techniques: Flow Cytometry, Analysis, Expressing, Fluorescence, Control, Western Blot, Immunofluorescence, Staining, Live Cell Imaging, RNA Sequencing

A. Antibody-binding capacity of ALPP/ALPPL2 in PDAC cells treated with DMSO, KRASi for 2 days (MRTX1133; 100 nM for AsPC-1, Panc0203, HPAC, SW1990, and PK-45H; 1 µM for PANC-1), or KRASi for 7 days (MRTX1133; 20 nM for AsPC-1, Panc0203, HPAC, SW1990, and PK-45H; 1 µM for PANC-1) as measured by flow cytometry. Each data point represents an independent experiment, error bars denote mean ± s.d., n = 3 independent repeats. Statistical significance was determined using two-way ANOVA followed by Tukey’s multiple comparisons test. B. Internalization of the indicated antibody or antibody-drug conjugate (10 nM) with or without KRASi (MRTX1133, 100 nM for AsPC-1 and SW1990) was quantified by total integrated density by Incucyte live-cell imaging. Internalization curves represent three technical replicates; error bars denote mean ± s.e.m, representative of three biological replicates. Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple comparisons test. C. Quantification of relative area coverage from crystal violet assays normalized to IgG-ADC control (AT-00-11A-MMAE). PDAC cells were treated with AT-00-11A-MMAE (5 nM), AT2604 (5 nM), or a combination of AT-00-11A-MMAE or AT2604 and KRASi (MRTX1133; 100 nM for AsPC-1, 10 nM for SW1990, 1 µM for PANC-1). Each data point represents a technical replicate; error bars denote mean ± s.d. Data is representative of 3 biological replicates. Statistical significance was determined by performing Welch’s t-test. D. Tumor volume growth curve of HPAC tumor-bearing mice treated with vehicle, AT-00-11A-MMAE or two different doses of AT2604 (n=6 mice per arm) twice weekly by IV injection. Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple comparisons test. E. Immunoblotting analysis of ALPP/ALPPL2, phospho-ERK (Thr202/Tyr205), and ERK protein levels in PDAC PDOs treated with RASi (RMC-6236, 100 nM) for 48 hours. F. Top, relative viability of PDAC PDOs treated with a dose response of RMC-6236 alone or in combination with increasing doses of AT2604 for 6 days. Each data point represents the mean of triplicates ± s.d.; viability curves shown are representative of three independent experiments. Bottom, Highest Single Agent synergy score values and heatmaps from data represented above. Tiles in heat map represent HSA synergy scores (red = synergy, white = additivity, green = antagonism). G. IHC images of SW1990 and AsPC-1 tumors stained for ALPP/ALPPL2 or pERK (T202/Y204) treated with 10 mg/kg once daily RMC-6236 for 3 and 7 days. Scale bars = 50 µm. H. Quantification of human ALPP/ALPPL2 from serum of mice from G treated with 10 mg/kg once daily RMC-6236 for 3 or 7 days (RMC-6236) as measured by ELISA, circles = 3 days, triangles = 7 days. Significance was determined by Welch’s t test. Statistical significance was determined by performing Welch’s t-test. I. Average tumor volume of subcutaneous SW1990 xenograft tumors treated with AT-00-11A-MMAE (3 mg/kg IV QW x 2) and vehicle, AT2604 (3 mg/kg IV QW x 2) and vehicle, RMC-6236 (10 mg/kg PO QD x 14) and AT-00-11A-MMAE, or AT2604 and RMC-6236. n = 9-11 mice per arm. Each point represents mean tumor volume ± s.e.m. Statistical significance was determined using two-way ANOVA followed by Tukey’s multiple comparisons test. J. Percent change of individual tumor volumes on day 27 relative to day 0. Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple comparisons test. K. Kaplan-Meier curve quantifying the probability of survival over time for each treatment arm. Statistical analysis was determined by Mantel-Cox test. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001; ns, not significant.

Journal: bioRxiv

Article Title: KRAS inhibition drives adaptive surfaceome remodeling and reveals ALPP/ALPPL2 as a targetable vulnerability in pancreatic cancer

doi: 10.64898/2026.10.01.756025

Figure Lengend Snippet: A. Antibody-binding capacity of ALPP/ALPPL2 in PDAC cells treated with DMSO, KRASi for 2 days (MRTX1133; 100 nM for AsPC-1, Panc0203, HPAC, SW1990, and PK-45H; 1 µM for PANC-1), or KRASi for 7 days (MRTX1133; 20 nM for AsPC-1, Panc0203, HPAC, SW1990, and PK-45H; 1 µM for PANC-1) as measured by flow cytometry. Each data point represents an independent experiment, error bars denote mean ± s.d., n = 3 independent repeats. Statistical significance was determined using two-way ANOVA followed by Tukey’s multiple comparisons test. B. Internalization of the indicated antibody or antibody-drug conjugate (10 nM) with or without KRASi (MRTX1133, 100 nM for AsPC-1 and SW1990) was quantified by total integrated density by Incucyte live-cell imaging. Internalization curves represent three technical replicates; error bars denote mean ± s.e.m, representative of three biological replicates. Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple comparisons test. C. Quantification of relative area coverage from crystal violet assays normalized to IgG-ADC control (AT-00-11A-MMAE). PDAC cells were treated with AT-00-11A-MMAE (5 nM), AT2604 (5 nM), or a combination of AT-00-11A-MMAE or AT2604 and KRASi (MRTX1133; 100 nM for AsPC-1, 10 nM for SW1990, 1 µM for PANC-1). Each data point represents a technical replicate; error bars denote mean ± s.d. Data is representative of 3 biological replicates. Statistical significance was determined by performing Welch’s t-test. D. Tumor volume growth curve of HPAC tumor-bearing mice treated with vehicle, AT-00-11A-MMAE or two different doses of AT2604 (n=6 mice per arm) twice weekly by IV injection. Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple comparisons test. E. Immunoblotting analysis of ALPP/ALPPL2, phospho-ERK (Thr202/Tyr205), and ERK protein levels in PDAC PDOs treated with RASi (RMC-6236, 100 nM) for 48 hours. F. Top, relative viability of PDAC PDOs treated with a dose response of RMC-6236 alone or in combination with increasing doses of AT2604 for 6 days. Each data point represents the mean of triplicates ± s.d.; viability curves shown are representative of three independent experiments. Bottom, Highest Single Agent synergy score values and heatmaps from data represented above. Tiles in heat map represent HSA synergy scores (red = synergy, white = additivity, green = antagonism). G. IHC images of SW1990 and AsPC-1 tumors stained for ALPP/ALPPL2 or pERK (T202/Y204) treated with 10 mg/kg once daily RMC-6236 for 3 and 7 days. Scale bars = 50 µm. H. Quantification of human ALPP/ALPPL2 from serum of mice from G treated with 10 mg/kg once daily RMC-6236 for 3 or 7 days (RMC-6236) as measured by ELISA, circles = 3 days, triangles = 7 days. Significance was determined by Welch’s t test. Statistical significance was determined by performing Welch’s t-test. I. Average tumor volume of subcutaneous SW1990 xenograft tumors treated with AT-00-11A-MMAE (3 mg/kg IV QW x 2) and vehicle, AT2604 (3 mg/kg IV QW x 2) and vehicle, RMC-6236 (10 mg/kg PO QD x 14) and AT-00-11A-MMAE, or AT2604 and RMC-6236. n = 9-11 mice per arm. Each point represents mean tumor volume ± s.e.m. Statistical significance was determined using two-way ANOVA followed by Tukey’s multiple comparisons test. J. Percent change of individual tumor volumes on day 27 relative to day 0. Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple comparisons test. K. Kaplan-Meier curve quantifying the probability of survival over time for each treatment arm. Statistical analysis was determined by Mantel-Cox test. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001; ns, not significant.

Article Snippet: AsPC-1, Panc1, Panc0203, Panc0403, HPAC, and SW1990 cells were obtained from ATCC, and SUIT2, KP-4, KP-1N were obtained from the JCRB Cell Bank.

Techniques: Binding Assay, Flow Cytometry, Live Cell Imaging, Control, IV Injection, Western Blot, Analysis, Staining, Enzyme-linked Immunosorbent Assay, Xenograft Assay

Journal: Cell Reports Medicine

Article Title: A bispecific nanobody-drug conjugate targeting TROP2 and c-Met for low-concentration, single-dose treatment of pancreatic cancer

doi: 10.1016/j.xcrm.2026.102688

Figure Lengend Snippet:

Article Snippet: HPAC , ATCC , CRL-2119TM.

Techniques: Recombinant, Virus, Microarray, Labeling, CCK-8 Assay, Expressing, Plasmid Preparation, Luciferase, Software